Article Text

PDF
P075 Efficacy and safety of switching to EVG/COBI/FTC/TAF in virologically suppressed women
  1. Sally Hodder1,
  2. Kathleen Squires2,
  3. Cissy Kityo3,
  4. Anchalee Avihingsanon4,
  5. Yulia Plotnikova5,
  6. Shuping Jiang6,
  7. Rima Kulkarni6,
  8. Andrew Cheng6,
  9. Cindy Elliott7,
  10. Huyen Cao6
  1. 1West Virginia Clinical and Translational Science Institute, Morgantown, WA, USA
  2. 2Thomas Jefferson University, Philadelphia, PA, USA
  3. 3Joint Clinical Research Centre, Kampala, Uganda
  4. 4The Thai Red Cross AIDS Research Centre, Bangkok, Thailand
  5. 5Irkutsk Regional Centre for Prevention and Control of AIDS and Infectious Diseases, Irkutsk, Russia
  6. 6Gilead Sciences Inc, Foster City, CA, USA
  7. 7Gilead Sciences Ltd, London, UK

Abstract

Introduction Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate(E/C/F/TDF) demonstrated superior efficacy when compared with atazanavir boosted by ritonavir(ATV/r+F/TDF) in 575 treatment naïve women at Week(W) 48. We now report the safety and efficacy of subsequent switching to E/C/F/tenofovir alafenamide(TAF) versus remaining on ATV/r+F/TDF.

Methods After completing the initial randomised, blinded 48-week trial,women on ATV/r+F/TDF were randomised 3:1 to receive open label E/C/F/TAF versus remaining on their current regimen. Viral suppression by FDA snapshot analysis, pre-defined bone and renal safety and tolerability endpoints 48 weeks after switch are reported. Women who become pregnant while on study are given the option to continue study drug.

Results 212 HIV-infected, virologically suppressed women were randomised(E/C/F/TAF n=159, ATV/r+F/TDF n=53). Virologic suppression(<50c/mL) was maintained in 94.3% on E/C/F/TAF vs 86.8% on ATV/r+F/TDF with virologic failure in 1.9%, 3.8%, respectively. More women on E/C/F/TAF achieved <20c/mL at W48 compared with ATV/r+F/TDF (84.9% versus 71.7%p=0.041). No treatment emergent resistance was detected in either group. Mean% increase in BMD was higher in the TAF group for both lumbar spine and total hip. Multiple markers of renal safety were improved for participants randomised to TAF. No cases of proximal renal tubulopathy were reported. Nineteen women became pregnant during the switch study 13 E/C/F/TAF, 6 ATV/r+F/TDF,3 normal infants have been delivered in each group to date.

Discussion These data demonstrate that women who switch to an integrase inhibitor+TAF-based regimen maintain high levels of virologic suppression with improvement in BMD and renal function biomarkers compared with those remaining on their ATV/r+TDF-based regimen.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.